Novartis (VTX:NOVN) has been given a CHF 87 price target by analysts at Bank of America in a research note issued on Wednesday. The brokerage presently has a “sell” rating on the stock. Bank of America’s price target indicates a potential upside of 5.71% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the company. set a CHF 90 target price on Novartis and gave the company a “buy” rating in a research report on Tuesday, September 19th. Baader Bank set a CHF 90 target price on Novartis and gave the stock a “buy” rating in a research note on Monday, October 30th. Berenberg Bank set a CHF 88 target price on Novartis and gave the stock a “neutral” rating in a research note on Monday, October 30th. Sanford C. Bernstein set a CHF 97 price target on Novartis and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, Societe Generale set a CHF 95 price target on Novartis and gave the company a “buy” rating in a research note on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of CHF 86.41.

Novartis (VTX NOVN) opened at CHF 82.30 on Wednesday. Novartis has a 1-year low of CHF 67.85 and a 1-year high of CHF 85.40.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/06/bank-of-america-analysts-give-novartis-novn-a-chf-87-price-target.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.